Rheumatoid Arthritis Trial, Recruiting (NCT00512239)

Rheumatoid Arthritis Trial, Recruiting NCT00512239 Sponsor: Gilles Boire Condition: Rheumatoid Arthritis

Printed from Voxsanity (voxsanity.com.au) — NCT00512239 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Rheumatoid Arthritis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with early rheumatoid arthritis (a condition where the immune system attacks the joints, causing pain and swelling)
You have been diagnosed with early inflammatory arthritis (joint inflammation that has been present for a short time)

Who may not be able to join:

You are unable or unwilling to give your consent to take part in the trial
You have arthritis caused by an infection (confirm with trial site)
You have arthritis caused by tiny crystals building up in the joints, such as gout (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gilles Boire, MD, MSc, Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Phone: (819) 564-5261

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT00512239

Sponsor: Gilles Boire

Phase: Not Applicable

Status: Recruiting

Condition: Rheumatoid Arthritis

Trial contact: (819) 564-5261

More information: https://clinicaltrials.gov/study/NCT00512239

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with early rheumatoid arthritis (a condition where the immune system attacks the joints, causing pain and swelling)
You have been diagnosed with early inflammatory arthritis (joint inflammation that has been present for a short time)

Who may not be able to join:

You are unable or unwilling to give your consent to take part in the trial
You have arthritis caused by an infection (confirm with trial site)
You have arthritis caused by tiny crystals building up in the joints, such as gout (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Gilles Boire

Registry

ClinicalTrials.gov

Start date

1 July 1998

Est. completion

1 December 2030

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Role of anti-Sa antibodies as predictor of severe radiographical damage

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov